What is PT-141? PT-141, also known as bremelanotide, is a melanocortin-receptor agonist studied for its effects on melanocortin signaling and sexual-behavior pathways. Research Areas Melanocortin receptor activity Neurological signaling Sexual-behavior research Libido-related research Central nervous system pathways Receptor-response research Why is it being researched? Unlike many experimental peptides, bremelanotide has undergone substantial clinical investigation. Its mechanism involves melanocortin receptors rather than the traditional pathways targeted by PDE-5 inhibitors. PRIMAL RESEARCH NOTE: Bremelanotide is an approved prescription medication in the United States for a specific indication, but this Primal research product is not represented as an approved prescription product.